Skip to main content
TipRanks
Go Ultimate75% OFF

AlzeCure Pharma AB (AC6) Stock Price & Analysis

3 Followers

AC6 Stock Chart & Stats

€0.54-€0.03(-4.96%)
At close: 5:30 PM GMT+1
€0.55€0.6€0.65€0.7Aug 21Sep 1Sep 15Oct 27
Day’s Range
EUR 0.54 - EUR 0.55
52-Week Range
EUR 0.07 - EUR 0.74
Previous Close
EUR 0.56
Volume
N/A
Average Volume (3M)
57
Market Cap
EUR 79.47M
Enterprise Value
EUR 849.11M
Total Cash (Recent Filing)
EUR 231.93M
Total Debt (Recent Filing)
EUR 1.72M
Price to Earnings (P/E)
10.7
Beta
-0.37
Next Earnings
Feb 23, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

The company has comparatively low financial leverage, which limits interest and refinancing pressure relative to its equity base. This provides more balance-sheet flexibility than a highly indebted biotech and can help preserve strategic options while pipeline programs progress.

Proprietary CNS Pipeline

A proprietary small-molecule pipeline gives AlzeCure control over internally generated drug candidates and potential intellectual-property value. Concentration on major CNS conditions such as Alzheimer’s disease and pain also targets areas with substantial unmet medical needs.

Partnering-based Monetization

The partnering model offers a path to monetize research without requiring AlzeCure to fund every development and commercialization stage alone. Successful deals could provide upfront and milestone payments, while royalties may create longer-term income from partnered products.

Bears Say

No Commercial Revenue

Zero reported revenue means the company has not yet established a commercial income stream to offset research and development spending. Until a candidate is partnered successfully or reaches approval, financial performance remains dependent on funding rather than recurring product sales.

Persistent Operating Losses

Large and persistent losses show that current operating costs materially exceed any income generated by the business. Worsening losses in the latest periods could accelerate depletion of financial resources and increase the capital required to advance the pipeline.

Heavy Cash Burn And Funding Need

Substantial negative operating and free cash flow indicates that the company is consuming cash to sustain development rather than generating internal funding. Continued burn increases dependence on future financing or partnerships and may constrain the pace and scope of pipeline investment.

AC6 FAQ

What was AlzeCure Pharma AB’s price range in the past 12 months?
AlzeCure Pharma AB lowest stock price was €0.07 and its highest was €0.74 in the past 12 months.
What is AlzeCure Pharma AB’s market cap?
AlzeCure Pharma AB’s market cap is €79.47M.
When is AlzeCure Pharma AB’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were AlzeCure Pharma AB’s earnings last quarter?
AlzeCure Pharma AB released its earnings results on Nov 11, 2026. The company reported €0.033 earnings per share for the quarter.
Is AlzeCure Pharma AB overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does AlzeCure Pharma AB pay dividends?
AlzeCure Pharma AB does not currently pay dividends.
What is AlzeCure Pharma AB’s EPS estimate?
AlzeCure Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AlzeCure Pharma AB have?
AlzeCure Pharma AB has 137,897,340 shares outstanding.
What happened to AlzeCure Pharma AB’s price movement after its last earnings report?
AlzeCure Pharma AB reported an EPS of €0.033 in its last earnings report. Following the earnings report the stock price went up 3.309%.
Which hedge fund is a major shareholder of AlzeCure Pharma AB?
Currently, no hedge funds are holding shares in DE:AC6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology